Stock Track | Insmed Plummets 5.07% as Q1 Earnings Miss Estimates and Wider Losses Disappoint Investors

Stock Track

08 May

Shares of Insmed (NASDAQ: INSM) plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.

Insmed reported a Q1 net loss of $1.42 per diluted share, significantly worse than the $1.06 loss per share in the same quarter last year and missing the FactSet analyst consensus estimate of $1.34 per share. The company's net loss for the quarter reached $256.6 million, also surpassing the expected loss of $240.4 million. Despite the challenges on the bottom line, Insmed's Q1 revenue showed some positive momentum, coming in at $92.8 million, slightly above the analyst estimate of $92.1 million and representing a 22.94% increase from the previous year.

Adding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook falls short of the $468.4 million expected by analysts polled by FactSet, suggesting potential headwinds in the company's growth trajectory. The combination of wider losses, missed earnings estimates, and a conservative revenue forecast appears to have dampened investor enthusiasm, leading to the significant stock decline during Thursday's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143843736"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143843736\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1143843736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143843736","market":"us","top_or_hot":-1,"title":"Stock Track | Insmed Plummets 5.07% as Q1 Earnings Miss Estimates and Wider Losses Disappoint Investors","media":"Stock Track","content":"<p>Shares of Insmed (NASDAQ: INSM) plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.</p>\n\n<p>Insmed reported a Q1 net loss of $1.42 per diluted share, significantly worse than the $1.06 loss per share in the same quarter last year and missing the FactSet analyst consensus estimate of $1.34 per share. The company's net loss for the quarter reached $256.6 million, also surpassing the expected loss of $240.4 million. Despite the challenges on the bottom line, Insmed's Q1 revenue showed some positive momentum, coming in at $92.8 million, slightly above the analyst estimate of $92.1 million and representing a 22.94% increase from the previous year.</p>\n\n<p>Adding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook falls short of the $468.4 million expected by analysts polled by FactSet, suggesting potential headwinds in the company's growth trajectory. The combination of wider losses, missed earnings estimates, and a conservative revenue forecast appears to have dampened investor enthusiasm, leading to the significant stock decline during Thursday's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insmed Plummets 5.07% as Q1 Earnings Miss Estimates and Wider Losses Disappoint Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insmed Plummets 5.07% as Q1 Earnings Miss Estimates and Wider Losses Disappoint Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-08 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Insmed (NASDAQ: INSM) plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.</p>\n\n<p>Insmed reported a Q1 net loss of $1.42 per diluted share, significantly worse than the $1.06 loss per share in the same quarter last year and missing the FactSet analyst consensus estimate of $1.34 per share. The company's net loss for the quarter reached $256.6 million, also surpassing the expected loss of $240.4 million. Despite the challenges on the bottom line, Insmed's Q1 revenue showed some positive momentum, coming in at $92.8 million, slightly above the analyst estimate of $92.1 million and representing a 22.94% increase from the previous year.</p>\n\n<p>Adding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook falls short of the $468.4 million expected by analysts polled by FactSet, suggesting potential headwinds in the company's growth trajectory. The combination of wider losses, missed earnings estimates, and a conservative revenue forecast appears to have dampened investor enthusiasm, leading to the significant stock decline during Thursday's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1143843736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143843736","pubTimestamp":1746715999,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Insmed  plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.Adding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"股票追踪Insmed暴跌5.07%，第一季度盈利未达预期且亏损扩大令投资者失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"Shares of Insmed (NASDAQ: INSM) plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.\nInsmed reported a Q1 net loss of $1.42 per diluted share, significantly worse than the $1.06 loss per share in the same quarter last year and missing the FactSet analyst consensus estimate of $1.34 per share. The company's net loss for the quarter reached $256.6 million, also surpassing the expected loss of $240.4 million. Despite the challenges on the bottom line, Insmed's Q1 revenue showed some positive momentum, coming in at $92.8 million, slightly above the analyst estimate of $92.1 million and representing a 22.94% increase from the previous year.\nAdding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook falls short of the $468.4 million expected by analysts polled by FactSet, suggesting potential headwinds in the company's growth trajectory. The combination of wider losses, missed earnings estimates, and a conservative revenue forecast appears to have dampened investor enthusiasm, leading to the significant stock decline during Thursday's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}